Kiniksa Pharmaceuticals International, plc develops and commercializes novel therapies for diseases with unmet need, with a focus on cardiovascular indications. News about Kiniksa commonly covers ARCALYST (rilonacept), an IL-1α and IL-1β cytokine trap approved by the FDA for recurrent pericarditis and other autoinflammatory indications.
Company updates also address ARCALYST commercial performance, patient-awareness initiatives in recurrent pericarditis, quarterly and annual financial results, and portfolio execution. Additional recurring themes include the KPL-387 recurrent pericarditis program, KPL-1161 IL-1 receptor antagonist development, corporate updates, and healthcare conference presentations.
Kiniksa Pharmaceuticals (KNSA) reported net product revenue of $39.9 million for Q4 2022 and $122.5 million for full-year 2022. The company's cash reserves of $190.4 million are projected to support operations through 2025. Kiniksa has enrolled 2 of 3 cohorts in the Phase 2 trial of KPL-404 for rheumatoid arthritis, with results expected in 1H 2024. The company aims to grow its cardiovascular franchise through ARCALYST sales and collaborative agreements for mavrilimumab, indicating a focus on strategic portfolio optimization.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 1:30 p.m. PT (4:30 p.m. ET). The presentation will be accessible via a live webcast on the company’s website, with a replay available within approximately 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for diseases with significant unmet medical needs, featuring assets like ARCALYST®, KPL-404, and mavrilimumab, which aim to address underserved conditions by modulating immunological pathways.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced participation in the Bank of America Securities 2022 Biotech SMID Cap Conference, set for December 7, 2022, at 10:15 a.m. Eastern Time. This event will feature a fireside chat with management. Investors can access a live webcast via the company's website, with a replay available approximately 48 hours post-event. Kiniksa is dedicated to developing therapeutic medicines for serious diseases and boasts a portfolio that includes ARCALYST®, KPL-404, and mavrilimumab.
Kiniksa Pharmaceuticals, Ltd. (KNSA) will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022, at 10:05 a.m. ET. A live webcast will be available on Kiniksa's website, with a replay accessible within 48 hours after the event. Kiniksa focuses on developing therapeutic medicines for debilitating diseases with significant unmet medical needs, featuring assets like ARCALYST®, KPL-404, and mavrilimumab, which target underserved conditions and modulate immunological pathways.
Kiniksa Pharmaceuticals reported Q3 2022 net revenue of $99.1 million, significantly up from $12.1 million in Q3 2021. ARCALYST net revenue was $33.4 million, with promising long-term data showing a 98.2% risk reduction in recurrent pericarditis events beyond 18 months (Hazard Ratio = 0.018, p0.0001). The company anticipates ARCALYST full-year revenues of and has cash reserves of $200.7 million to fund operations into at least 2025.
Kiniksa Pharmaceuticals, Ltd. (KNSA) announced a conference call and live webcast on November 1, 2022, at 8:30 a.m. ET to discuss its third quarter 2022 financial results and corporate activities. Interested participants can access the call via Kiniksa's website or register for telephone participation. A replay will be available approximately 48 hours after the event. Kiniksa focuses on developing therapeutic medicines addressing significant unmet medical needs, with assets including ARCALYST, KPL-404, and mavrilimumab.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has finalized a global license agreement with Roche and Genentech for the development of vixarelimab, a monoclonal antibody targeting oncostatin M receptor beta (OSMRβ). Kiniksa will receive $100 million upfront: $80 million within 30 days and $20 million post-delivery of drug supplies. Additionally, Kiniksa could earn up to $600 million in milestones and royalties based on sales. The company expects this funding to sustain its operations through at least 2025.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced participation in the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 2:55 p.m. ET. The management will engage in a fireside chat, showcasing the company’s commitment to addressing unmet medical needs through innovative biopharmaceuticals.
A live webcast will be available on Kiniksa’s website, with a replay accessible 48 hours after the event, ensuring broad outreach to investors and stakeholders.
Kiniksa Pharmaceuticals reported Q2 2022 net revenue of $27 million from ARCALYST, marking a significant increase from $7.7 million in Q2 2021. The company expects full-year ARCALYST revenue between $115 million and $130 million. An upfront payment of $100 million is anticipated from a global license agreement with Genentech for vixarelimab, which will support operations into at least 2025. Kiniksa's net loss narrowed to $20 million from $41.6 million year-over-year. The company plans to enhance its sales team in Q4 2022.
Kiniksa Pharmaceuticals (KNSA) has entered a global licensing agreement with Roche and Genentech for the development and commercialization of vixarelimab, a monoclonal antibody targeting OSMRβ. Kiniksa will receive $100 million upfront and is eligible for up to $600 million in future milestones, along with royalties on net sales. The deal focuses on fibrotic indications where OSMRβ plays a critical role. Kiniksa plans to use the non-dilutive capital to expand its ARCALYST cardiovascular franchise. This agreement highlights Kiniksa's commitment to addressing significant unmet medical needs.